Safety of direct antiviral agents in the management of hepatitis C

References

• Jazwinski A, Muir A. Direct-acting antiviral medications for chronic hepatitis C virus infection. Gastroenterol Hepatol (N Y). 2011;7(3):154–162.
   PubMedGoogle Scholar
• Asselah T, Marcellin P. New direct-acting antivirals’ combination for the treatment of chronic hepatitis C. Liver Int. 2011;31(1):68–77.
   PubMed Web of Science ®Google Scholar
• Calleja JL, Pascasio JM, Ruiz-Antorán B, et al. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis. Liver Int. 2015;35(1):90–100.
   PubMed Web of Science ®Google Scholar
• Lontok E, Harrington P, Howe A, et al. Hepatitis C virus drug resistance–associated substitutions: state of the art. Hepatology. 2015;62(5):1623–1632.
   PubMed Web of Science ®Google Scholar
• Paolucci S, Fiorina L, Piralla A, et al. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J. 2012;9:245.
   PubMed Web of Science ®Google Scholar
• Burger D, Back D, Buggisch P, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol. 2013;58:792–800.
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Burton JRJ, Everson GT. Drug-drug interactions during antiviral therapy for chronic hepatitis C. Nat Rev Gastroenterol Hepatol. 2013;10(10):596–606.
   PubMed Web of Science ®Google Scholar
• Kwo PY. Boceprevir: a novel nonstructural 3 (NS3) protease inhibitor for the treatment of chronic hepatitis C infection. Therap Adv Gastroenterol. 2012;5(3):179–188.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199–236.
   PubMed Web of Science ®Google Scholar
• Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364(13):1195–1206.
   PubMed Web of Science ®Google Scholar
• Lens S, Calleja JL, Campillo A, et al. Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis C. World J Gastroenterol. 2015 May 7;21(17):5421–5426.
   PubMed Web of Science ®Google Scholar
• Hézode C. Boceprevir and telaprevir for the treatment of chronic hepatitis C: safety management inclinical practice. Liver Int. 2012;32(1):32–38.
   PubMed Web of Science ®Google Scholar
• Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–1217.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–2416.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011;364:2417–2428.
   PubMed Web of Science ®Google Scholar
• Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther. 2012;35(6):647–662.
   PubMed Web of Science ®Google Scholar
• Torii H, Sueki H, Kumada H, et al. Dermatological side-effects of telaprevir-based triple therapy for chronic hepatitis C in phase III trials in Japan. J Dermatol. 2013;40(8):587–595.
   PubMed Web of Science ®Google Scholar
• Hézode C1, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French early access programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434–441.
   PubMed Web of Science ®Google Scholar
• Wilby KJ, Greanya ED, Ford JA, et al. A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol. 2012;11(2):179–185.
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research. Application number: NDA 205123/S-008. Reference ID: 3718944 [cited 2016 Jan 20]. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2015/205123Orig1s008.pdf
   Google Scholar
• INITIAL TREATMENT OF HCV INFECTION. AASLD. Published on recommendations for testing, managing, and treating hepatitis C [cited 2016 Jan 20]. Available from: www.hcvguidelines.org/full-report/initial-treatment-hcv-infection
   Google Scholar
• Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77–87.
   PubMed Web of Science ®Google Scholar
• Poveda E, Wyles DL, Mena A, et al. Update on hepatitis C virus resistance to direct-acting antiviral agents. Antiviral Res. 2014;108:181–191.
   PubMed Web of Science ®Google Scholar
• Elbaz T, El-Kassas M, Esmat G. New era for management of chronic hepatitis C virus using direct antiviral agents: a review. J Adv Res. 2015;6(3):301–310.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non responders to pegylated interferon and ribavirin and treatment naïve patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–1765.
   PubMed Web of Science ®Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669–1679.e3.
   PubMed Web of Science ®Google Scholar
• FDA approves Sovaldi for chronic hepatitis C. FDA NEWS RELEASE [cited 2016 Jan 20]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377888.htm
   Google Scholar
• Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867–1877.
   PubMed Web of Science ®Google Scholar
• Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44.
   PubMed Web of Science ®Google Scholar
• Supplementary Appendix to Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887 [cited 2016 Jan 19]. Available from: www.nejm.org/doi/suppl/10.1056/NEJMoa1214853/suppl_file/nejmoa1214853_appendix.pdf
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Stepanova M, Zeuzem S, et al. Patient reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study. J Hepatol. 2014;61(2):228–234.
   PubMed Web of Science ®Google Scholar
• Molina JM, Orkin C, Iser DM, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised,phase 3 study. Lancet. 2015;385(9973):1098–1106.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887.
   PubMed Web of Science ®Google Scholar
• Doss W, Shiha G, Hassany M, et al. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol. 2015;63(3):581–585.
   PubMed Web of Science ®Google Scholar
• Svarovskaia ES, Dvory-Sobol H, Parkin N, et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus – infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014 Dec 15;59(12):1666–1674.
   PubMed Web of Science ®Google Scholar
• Sofosbuvir: HIGHLIGHTS OF PRESCRIBING INFORMATION [cited 2016 Jan 19]. Available from: www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf
   Google Scholar
• Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015;47(12):924–929.
   PubMed Web of Science ®Google Scholar
• Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61(4):1127–1135.
   PubMed Web of Science ®Google Scholar
• DAKLINZA AK(daclatasvir): HIGHLIGHTS OF PRESCRIBING INFORMATION [cited 2016 Jan 19]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2015/206843Orig1s000lbl.pdf
   Google Scholar
• DRUG INTERACTIONS WITH NEW/INVESTIGATIONAL HEPATITIS C NS5A INHIBITORS. Academic copyright: Alice Tseng, Pharm.D., FCSHP, AAHIVP, Toronto General Hospital and Pierre Giguere, M.Sc.Phm., The Ottawa Hospital www.hcvdruginfo.ca. 2015 May 28 [cited 2016 Jan 19]. Available from Hepatitis C New/Investigational NS5A Inhibitors: www.hcvdruginfo.ca/tables/html
   Google Scholar
• Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus sofosbuvir for HCV in patients co-infected with HIV-1. N Engl J Med. 2015;373(8):714–725.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370(3):211–221.
   PubMed Web of Science ®Google Scholar
• Link JO, Taylor JG, Xu L, et al. Discovery of ledipasvir (GS-5885): a potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection. J Med Chem. 2014 Mar 13;57(5):2033–2046.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed dose combination with and without ribavirin in treatment-naïve and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2trial. Lancet. 2014;383(9916):515–523.
   PubMed Web of Science ®Google Scholar
• Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. Jama. 2015 Mar 24-31;313(12):1232–1239.
   PubMed Web of Science ®Google Scholar
• Townsend K, Petersen T, Gordon LA, et al. Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. Aids. 2016;30(2):261–266.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014 May 15;370(20):1889–1898.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014 Apr 17;370(16):1483–1493.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879–1888.
   PubMed Web of Science ®Google Scholar
• Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373(8):705–713.
   PubMed Web of Science ®Google Scholar
• Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015 Sep;149(3):649–659.
   PubMed Web of Science ®Google Scholar
• Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16(6):685–697.
   PubMed Web of Science ®Google Scholar
• Harvoni™a(ledipasvir and sofosbuvir): HIGHLIGHTS OF PRESCRIBING INFORMATION [cited 2016 Jan 19]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/205834s000lbl.pdf
   Google Scholar
• Raedler LA. Viekira Pak (Ombitasvir, Paritaprevir, and Ritonavir tablets; Dasabuvir tablets): all-oral fixed combination approved for genotype 1 chronic hepatitis C infection. Am Health Drug Benefits. 2015;8(Spec Feature):142–147.
   PubMedGoogle Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24;370(17):1594–1603.
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1604–1614.
   PubMed Web of Science ®Google Scholar
• Andreone P, Colombo MG, Enejosa JV, et al. ABT 450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–365.e1.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r – ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014 May 22;370(21):1983–1992.
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r, ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370(21):1973–1982.
   PubMed Web of Science ®Google Scholar
• VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets), co-packaged for oral use: HIGHLIGHTS OF PRESCRIBING INFORMATION [cited 2016 Jan 19]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2015/206619s008lbl.pdf
   Google Scholar
• Smith MA, Lim A. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015 Nov 13;9:6083–6094.
   PubMed Web of Science ®Google Scholar